These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 35210538

  • 1. Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas.
    Hachisuga T, Murakami M, Harada H, Ueda T, Kurita T, Kagami S, Yoshino K, Tajiri R, Hisaoka M.
    Sci Rep; 2022 Feb 24; 12(1):3153. PubMed ID: 35210538
    [Abstract] [Full Text] [Related]

  • 2. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
    Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK.
    Gynecol Oncol; 2014 Jun 24; 133(3):473-9. PubMed ID: 24674832
    [Abstract] [Full Text] [Related]

  • 3. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas S, Silva-Ayala R, Almaraz M, Méndez C.
    J Ovarian Res; 2016 Jul 07; 9(1):41. PubMed ID: 27388275
    [Abstract] [Full Text] [Related]

  • 4. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C, Xue Y, Li Y, Bu H, Yu H, Zhang T, Zhang Z, Yan S, Lu N, Kong B.
    Int J Gynecol Cancer; 2018 Jan 07; 28(1):51-58. PubMed ID: 28976449
    [Abstract] [Full Text] [Related]

  • 5. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis.
    Sallum LF, Andrade L, Ramalho S, Ferracini AC, de Andrade Natal R, Brito ABC, Sarian LO, Derchain S.
    Oncotarget; 2018 Mar 23; 9(22):15818-15827. PubMed ID: 29662608
    [Abstract] [Full Text] [Related]

  • 6. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A, Tamiolakis D, Matalliotaki C, Karvela-Kalogeraki I, Karvelas-Kalogerakis M, Segredakis J, Sinatkas V, Matalliotakis I.
    Rev Med Chir Soc Med Nat Iasi; 2015 Mar 23; 119(2):454-60. PubMed ID: 26204652
    [Abstract] [Full Text] [Related]

  • 7. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX, Yu L, Bi R, Yang WT.
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug 23; 40(8):511-6. PubMed ID: 22169637
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
    Paik ES, Kim JH, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.
    J Gynecol Oncol; 2018 Jan 23; 29(1):e13. PubMed ID: 29185271
    [Abstract] [Full Text] [Related]

  • 9. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
    Wang A, Lu L, Wang Y, Sun Y, Zhang Y, Guo C, Gu Y, Liu A.
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan 23; 43(1):20-4. PubMed ID: 24713244
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S, Yin C, Zhang Y, Zhang L, Tao L, Liang W, Pang L, Fu R, Ding Y, Li F, Jia W.
    Biomed Res Int; 2019 Jan 23; 2019():2867372. PubMed ID: 31312656
    [Abstract] [Full Text] [Related]

  • 11. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
    Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM.
    J Surg Oncol; 2018 Feb 23; 117(2):236-244. PubMed ID: 28787528
    [Abstract] [Full Text] [Related]

  • 12. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A, Ozkan NT, Sarı ME, Celik H, Dede M, Akbayır Ö, Güngördük K, Şahin H, Haberal A, Güngör T, Arvas M, Meydanlı MM.
    J Gynecol Oncol; 2018 Jan 23; 29(1):e12. PubMed ID: 29185270
    [Abstract] [Full Text] [Related]

  • 13. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    J Ovarian Res; 2019 May 07; 12(1):40. PubMed ID: 31064392
    [Abstract] [Full Text] [Related]

  • 14. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K, Yokoi A, Matsuzaki J, Kato T, Ochiya T, Kajiyama H, Yamamoto Y.
    Cancer Sci; 2021 Dec 07; 112(12):4977-4986. PubMed ID: 34618992
    [Abstract] [Full Text] [Related]

  • 15. Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
    Gynecol Oncol; 2021 Dec 07; 163(3):498-505. PubMed ID: 34602289
    [Abstract] [Full Text] [Related]

  • 16. Age is associated with prognosis in serous ovarian carcinoma.
    Deng F, Xu X, Lv M, Ren B, Wang Y, Guo W, Feng J, Chen X.
    J Ovarian Res; 2017 Jun 12; 10(1):36. PubMed ID: 28606125
    [Abstract] [Full Text] [Related]

  • 17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct 25; 52(10):687-696. PubMed ID: 29060967
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
    Chung YS, Park SY, Lee JY, Park JY, Lee JW, Kim HS, Suh DS, Kim YH, Lee JM, Kim M, Choi MC, Shim SH, Lee KH, Song T, Hong JH, Lee WM, Lee B, Lee IH.
    BMC Cancer; 2019 Apr 11; 19(1):341. PubMed ID: 30971221
    [Abstract] [Full Text] [Related]

  • 19. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr 11; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 20. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
    De Donato M, Babini G, Mozzetti S, Buttarelli M, Ciucci A, Arduini G, De Rosa MC, Scambia G, Gallo D.
    J Exp Clin Cancer Res; 2020 Nov 30; 39(1):265. PubMed ID: 33250051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.